Hematology-Oncology – Page 4

$ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia$

ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia

By MedXY 08/29/2025

The ZUMA-8 phase 1 study evaluates the safety and efficacy of brexucabtagene autoleucel, a CD19-directed CAR T-cell therapy, in relapsed/refractory CLL, showing promising response rates and manageable safety profiles, especially in patients with low tumor burden.

$Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study$

Hematology-Oncology Specialties

Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study

By MedXY 08/29/2025

This phase 2 trial evaluated modakafusp alfa, a novel immunocytokine targeting CD38+ cells, in heavily pretreated relapsed/refractory multiple myeloma, showing promising efficacy and manageable toxicity despite early termination.

$Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML$

Hematology-Oncology Specialties

Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML

By MedXY 08/29/2025

The phase 2 AUGMENT-101 study demonstrates that revumenib, a selective menin inhibitor, induces meaningful remissions and enables stem cell transplantation in heavily pretreated, older patients with relapsed or refractory NPM1-mutated AML, addressing a critical unmet need.

Hematology-Oncology Specialties

Pemigatinib: A Breakthrough Targeted Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements

By MedXY 08/28/2025

Pemigatinib demonstrates high efficacy and manageable toxicity in treating MLN-FGFR1, especially in chronic-phase patients, addressing a critical unmet need in this aggressive neoplasm.

Hematology-Oncology Specialties

Venous Thromboembolism in Newly Diagnosed Lymphoma Patients: Insights from a Real-World Vietnamese Cohort

By MedXY 08/26/2025

An 8.3% incidence of VTE was observed in newly diagnosed lymphoma patients in Vietnam, with pretreatment elevated D-dimer and cardiovascular comorbidities as key risk factors, emphasizing the need for tailored thromboprophylaxis.

$Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Clinical Updates Hematology-Oncology Specialties

Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma

By MedXY 08/23/2025

This phase 1 trial demonstrates that linperlisib combined with chidamide offers manageable safety and noteworthy efficacy in relapsed or refractory cutaneous T-cell lymphoma, providing a potential new all-oral therapeutic option for advanced disease.

$Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up$

Hematology-Oncology Specialties

Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up

By MedXY 08/21/2025

Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell lymphoma with a favorable safety profile.

Hematology-Oncology news Specialties

Can Eltrombopag Transform Aplastic Anemia Care?

By MedXY 08/19/2025

Eltrombopag combined with immunosuppressive therapy shows promising efficacy in severe aplastic anemia, especially in relapsed/refractory pediatric patients, with over half achieving hematologic responses and transfusion independence, supporting its growing role in treatment paradigms.

$Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial$

Clinical Updates Hematology-Oncology news Specialties

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial

By MedXY 08/07/2025

The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.

Clinical Updates Hematology-Oncology news Specialties

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

By MedXY 08/07/2025

Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.

$Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial$

Clinical Updates Hematology-Oncology news Specialties

Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial

By MedXY 08/07/2025

Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.

Clinical Updates Hematology-Oncology news Specialties

Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

By MedXY 08/07/2025

A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.

Clinical Updates Hematology-Oncology news Specialties

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

By MedXY 08/07/2025

A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.

Clinical Updates Hematology-Oncology news Specialties

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study

By MedXY 08/07/2025

This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side effects.

Clinical Updates Hematology-Oncology news Specialties

Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial

By MedXY 08/07/2025

KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.

Hematology-Oncology news Specialties Transplantation

Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial

By MedXY 08/07/2025

A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this population.

Clinical Updates Hematology-Oncology news Specialties

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY 08/07/2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxicity.

Clinical Updates Hematology-Oncology news Specialties

Hetrombopag vs. Thrombopoietin for Platelet Engraftment After Allogeneic Stem Cell Transplantation: New Evidence from a Multicenter Randomized Controlled Trial

By MedXY 08/06/2025

Hetrombopag demonstrates comparable efficacy and safety to thrombopoietin for platelet engraftment after allogeneic hematopoietic stem cell transplantation, offering a promising alternative in hematologic care.

Clinical Updates Hematology-Oncology news Specialties

Intermediate-Dose Cytarabine Matches High-Dose Efficacy with Fewer Side Effects in Postinduction AML Therapy

By MedXY 08/05/2025

A major RCT shows intermediate-dose cytarabine is noninferior to high-dose as postinduction therapy in AML, with similar survival and lower toxicity.

$Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results$

Clinical Updates Hematology-Oncology news Specialties

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

By MedXY 08/02/2025

The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.